Plain-English translation of ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing liposomal irinotecan combined with two other medications ( and ) as a second-line treatment for advanced pancreatic cancer—meaning cancer that has progressed after an initial round of chemotherapy. The study compares this three-drug combination against a standard two-drug treatment (liposomal irinotecan with and leucovorin) to see which approach works better and is safer for patients.
Most people with advanced pancreatic cancer need a second treatment option when their first chemotherapy stops working. This trial is exploring whether adding a third medication to the liposomal irinotecan might help more patients respond to treatment and live longer.
You likely qualify if…
You likely don't qualify if…
In this two-part study, you would receive treatment through an IV infusion every 2 weeks, with imaging scans to check your cancer response every 1.5 months. The first part involves finding the best dose of the three-drug combination; the second part compares your combination against the standard two-drug treatment. You will continue receiving treatment until your cancer progresses, you experience unacceptable side effects, or the study ends.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China